Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 22'nd Oct 2025
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
08:00am, Tuesday, 21'st Oct 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Awar
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
05:56pm, Monday, 20'th Oct 2025
On October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at $10.65 million based on average quarterl
Ionis to hold third quarter 2025 financial results webcast
07:05am, Thursday, 16'th Oct 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its thir
Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript
08:55pm, Tuesday, 07'th Oct 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Shareholder/Analyst Call October 7, 2025 8:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO &
Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on
08:33am, Tuesday, 07'th Oct 2025
Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
07:00am, Tuesday, 07'th Oct 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
03:16pm, Tuesday, 23'rd Sep 2025
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
09:06am, Monday, 22'nd Sep 2025
Ionis Pharmaceuticals, Inc. IONS released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fat
Ionis' brain disorder drug shows promise in clinical trial
07:10am, Monday, 22'nd Sep 2025
Ionis Pharmaceuticals said on Monday its experimental brain disorder drug met the main goal in an early-to-late-stage study.
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
07:00am, Monday, 22'nd Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexande
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
07:00am, Friday, 19'th Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
07:00am, Friday, 12'th Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally
Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)
02:14am, Thursday, 11'th Sep 2025
After years of futility, Ionis' recent regulatory and clinical successes have spurred optimistic market attention. I review Q2/2025 earnings documents together with 09/04/2025 CEO Monia interview and
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
12:16pm, Wednesday, 10'th Sep 2025
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
